Retrospective Cohort Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Dec 16, 2020; 12(12): 542-554
Published online Dec 16, 2020. doi: 10.4253/wjge.v12.i12.542
Crohn’s strictures open with anti-mycobacterial antibiotic therapy: A retrospective review
Rhys Collyer, Annabel Clancy, Gaurav Agrawal, Thomas J Borody
Rhys Collyer, Annabel Clancy, Gaurav Agrawal, Thomas J Borody, Centre for Digestive Diseases, Five Dock 2046, NSW, Australia
Author contributions: All authors contributed to conceptualization, investigation and validation; Collyer R and Clancy A performed data curation and formal analysis; Clancy A, Agrawal G and Borody TJ contributed to project administration and provided supervision; Agrawal G and Borody TJ contributed to resources; Collyer R performed visualization; all authors wrote the original draft, reviewed and edited the manuscript, and issued the final approval of the submitted version.
Institutional review board statement: The study was reviewed and approved by the Institutional Ethics Committee (STUDY NO. CDD19/C01) at Centre for Digestive Diseases, NSW, Australia.
Informed consent statement: A waiver of consent was granted for this study. Patients were not required to give informed consent for this study because the analysis used de-identified data that was obtained after each patient consented to the treatment.
Conflict-of-interest statement: Dr. Borody TJ reports personal fees from THE CENTRE FOR DIGESTIVE DISEASES, other from OTAKARO PATHWAY, other from FINCH THERAPEUTICS, other from REDHILL BIO, outside the submitted work; in addition, Dr. Borody TJ has a patent US16/233419 pending, a patent AU2018256633A1 pending, a patent WO2011050397A1 pending, a patent US20180344782A1 pending, a patent CA3003138A1 issued, a patent AU2011286165 issued, a patent AU20111286165B2 issued, a patent US9308226 issued, a patent US9198926 licensed, a patent US9072763 licensed, and a patent AU2010903474 issued.
Data sharing statement: All data relevant to the study are included in this article.
STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Thomas J Borody, AGAF, BSc, DSc, FACG, FACP, FRACP, MBBS, MD, PhD, Professor, Centre for Digestive Diseases, Level 1, 229 Great North Road, Five Dock 2046, NSW, Australia. thomas.borody@cdd.com.au
Received: October 2, 2020
Peer-review started: October 2, 2020
First decision: October 17, 2020
Revised: November 2, 2020
Accepted: November 17, 2020
Article in press: November 17, 2020
Published online: December 16, 2020
Core Tip

Core Tip: Crohn’s disease (CD) is a chronic, incurable inflammatory bowel disease rising in incidence and prevalence. Strictures are a significant complication of CD with current first-line treatments including dilatation and/or surgery. Mycobacterium avium ssp. paratuberculosis is a suspected causative agent in CD and the proposed treatment is anti-mycobacterial antibiotic therapy (AMAT). Preliminary results indicate AMAT for atypical Mycobacteria opens CD strictures efficaciously and reliably. Our study provides an alternative to endoscopic and surgical intervention to treat strictures in CD. Our findings should be validated by further randomized controlled trials.